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BACKGROUND
• Cardiovascular disease (CVD) is the leading cause of global mortality and was
responsible for about 17.8 million deaths worldwide in 2017, corresponding
to 330 million years of life lost and 35.6 million years of life lived with
disability.1

RESULTS
Figure 2. Risk of Bias Judgments for the Included Studies

• There is consistent evidence that higher neighborhood walkability scores are
associated with higher levels of physical activity and that physical inactivity
can independently increase one’s risk of developing CVD. 3,5

OBJECTIVE

METHODOLOGY
Figure 1. Literature Search and Screening Process

The body of evidence included in this review was
determined to be “insufficient” in conclusively supporting
a negative association between neighborhood walkability
and risk of CVD.
Limitations/Knowledge Gaps:
• Over half of the included studies were cross-sectional,
so they could not support causal inferences between
neighborhood walkability and CVD.
• The lack of standardized walkability measures that can
be used across different data systems and settings
• Variation in the assessment of cardiovascular risk
outcomes
• Unaddressed confounders: self-selection into walkable
neighborhoods and health-seeking behaviors

• Neighborhood walkability, or the extent to which the built environment is
accessible for utilitarian and leisure-time walking, is measured by using
spatial and computational models to aggregate local features like street
connectivity, land use mix, and residential density into a walkability index.4

To systematically review the current body of evidence assessing the
relationship between neighborhood walkability and risk of cardiovascular
disease in adults, as well as evaluate the strength of the evidence based on
the methodological quality of the included studies.

CONCLUSIONS
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Figure 3: Analysis of the Quality and Strength of Evidence

This review compellingly accentuates the need for the
development of longitudinal studies that use the
limitations of this evidence as a guide to more accurately
define the complex relationship between neighborhood
walkability and risk of CVD.
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Rating the Quality and Strength of Evidence
The quality and strength of the evidence was determined using methodology outlined
by the Navigation Guide.2 The risk of bias was evaluated for each included study and
incorporated into the quality of evidence decision, which was based on numerical
scores given to several downgrading and upgrading adjustment factors. Finally, the
strength of the evidence across all included studies was evaluated based on Navigation
Guide criteria to determine whether the evidence was sufficient to support a
relationship between the exposure and the outcome.
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